Reason, co-founder and CEO of Repair Biotechnologies and a longevity industry veteran with a background in astrophysics, joins us to talk about what it actually takes to test a therapy on humans, and why the system built to protect patients often keeps the best evidence hidden.
He breaks down why investors backing gene and cell therapies care more about a drug's earning potential than whether it works, and why some treatments already in use could be quietly adding years to human lifespan without anyone confirming it. Reason also shares what running his own clinical trial in Roatán taught him about Australia's regulatory advantage over the US, and how much of that difference comes down to culture and consensus rather than actual safety.
More about Reason’s work:
